We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-20.78%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$664M
AUM Growth
-$172M
Cap. Flow
+$85.8M
Cap. Flow %
12.92%
Top 10 Hldgs %
40.96%
Holding
86
New
4
Increased
14
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$22.2M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$17.1M
3
NKTR icon
Nektar Therapeutics
NKTR
+$15.8M
4
KA
Kineta, Inc. Common Stock
KA
+$13.6M
5
NVRO
NEVRO CORP.
NVRO
+$13M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$52.7M
2
BPMC
Blueprint Medicines
BPMC
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 86.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$36.7M 5.52%
1,497,475
+740,000
+98% +$17.1M
HRTX icon
2
Heron Therapeutics
HRTX
$94.1M
$33.2M 5.01%
1,750,000
+64,281
+4% +$1.27M
SAGE
3
DELISTED
Sage Therapeutics
SAGE
$30.3M 4.56%
945,000
+630,000
+200% +$22.2M
OMER icon
4
Omeros
OMER
$863M
$30.1M 4.53%
1,960,000
– –
NKTR icon
5
Nektar Therapeutics
NKTR
$2.41B
$27.5M 4.14%
133,333
+82,323
+161% +$15.8M
NVRO
6
DELISTED
NEVRO CORP.
NVRO
$27.3M 4.11%
485,386
+220,000
+83% +$13M
ALKS icon
7
Alkermes
ALKS
$8.39B
$23.9M 3.61%
700,000
– –
NBIX icon
8
Neurocrine Biosciences
NBIX
$18.7B
$23.9M 3.6%
603,900
– –
EGRX
9
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$20.3M 3.05%
500,000
+100,000
+25% +$6.34M
DVAX
10
DELISTED
Dynavax Technologies
DVAX
$18.8M 2.83%
975,000
+400,000
+70% +$8.08M
KA
11
DELISTED
Kineta, Inc. Common Stock
KA
$16.6M 2.51%
+12,333
New +$13.6M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$27.4B
$15.4M 2.32%
245,000
– –
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$14.3M 2.15%
700,000
+200,000
+40% +$6.35M
QTNT
14
DELISTED
Quotient Limited Ordinary Shares
QTNT
$13.4M 2.01%
37,978
– –
MGNX icon
15
MacroGenics
MGNX
$240M
$13.1M 1.98%
700,000
+200,000
+40% +$3.81M
CLLS
16
Cellectis
CLLS
$287M
$12.9M 1.94%
469,145
– –
TSRO
17
DELISTED
TESARO, Inc.
TSRO
$12.8M 1.93%
291,250
– –
CBPO
18
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$12.8M 1.92%
111,500
– –
ACRS icon
19
Aclaris Therapeutics
ACRS
$743M
$12.3M 1.85%
647,944
– –
CHRS icon
20
Coherus Oncology
CHRS
$227M
$12.1M 1.82%
569,130
– –
ARDX icon
21
Ardelyx
ARDX
$1.25B
$11.5M 1.73%
1,481,075
– –
VTAE
22
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$11.5M 1.73%
1,735,000
+1,111,591
+178% +$10.1M
SRNE
23
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$11.3M 1.7%
2,095,334
– –
NERV icon
24
Minerva Neurosciences
NERV
$187M
$10.8M 1.62%
219,118
+75,988
+53% +$3.24M
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.6M 1.6%
495,356
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Cormorant Asset Management held 86 positions worth $664M, down 21% from $836M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management deployed $85.8M of net new capital in Q1 2016, opening 4 new positions and adding to 14 existing holdings. Its largest new stake was Kineta, Inc. Common Stock: 12,333 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier.

On the sell side, the most notable exit was DYAX CORPORATION, an estimated $52.7M sold.

  • Cormorant Asset Management's largest Q1 2016 buy was Kineta, Inc. Common Stock: 12,333 shares worth $16.6M.
  • Cormorant Asset Management added most to Sage Therapeutics in Q1 2016, an estimated $22.2M increase.
  • Cormorant Asset Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $52.7M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $664M portfolio in Q1 2016.
  • Cormorant Asset Management opened 4 new positions and closed 2 in Q1 2016.
  • Cormorant Asset Management's portfolio value fell 21% quarter-over-quarter to $664M.

Based on Cormorant Asset Management's 13F filing for Q1 2016, filed 16 May 2016.